26,835 Shares in Glaukos Corporation $GKOS Purchased by Walleye Capital LLC

Walleye Capital LLC purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 26,835 shares of the medical instruments supplier’s stock, valued at approximately $3,750,000.

Several other large investors have also recently added to or reduced their stakes in GKOS. Janus Henderson Group PLC increased its holdings in shares of Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after buying an additional 2,329,608 shares in the last quarter. Wellington Management Group LLP raised its position in Glaukos by 10.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after purchasing an additional 336,266 shares during the last quarter. Primecap Management Co. CA boosted its stake in Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares in the last quarter. State Street Corp increased its stake in shares of Glaukos by 0.9% in the fourth quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock valued at $239,640,000 after buying an additional 18,040 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Glaukos by 3.5% in the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after buying an additional 68,497 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos Trading Down 2.3%

NYSE GKOS opened at $185.01 on Friday. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $190.00. The stock has a 50-day simple moving average of $151.24 and a 200 day simple moving average of $129.36. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $10.91 billion, a PE ratio of -56.93 and a beta of 0.78.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.24) EPS. Research analysts forecast that Glaukos Corporation will post -0.35 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on GKOS. BTIG Research boosted their target price on shares of Glaukos from $164.00 to $193.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Truist Financial lifted their target price on Glaukos from $180.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Citigroup boosted their target price on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Wells Fargo & Company lifted their price objective on Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and an average target price of $177.33.

Insider Buying and Selling

In other news, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer owned 72,588 shares of the company’s stock, valued at $13,046,967.12. The trade was a 45.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Leana Wen sold 525 shares of Glaukos stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the transaction, the director owned 21,092 shares in the company, valued at approximately $3,535,651.96. This represents a 2.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 110,525 shares of company stock valued at $19,125,006 in the last 90 days. 5.90% of the stock is owned by insiders.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.